Table 1.
Patient characteristics (n=652)
| No. of Patients | |||||
|---|---|---|---|---|---|
| Characteristic | All Patients (%) | Treatment Modality | P Value | ||
| 3D-CRT (%) | IMRT (%) | PBT (%) | |||
| Sex | |||||
| Male | 336 (52) | 202 (50) | 77 (55) | 59 (55) | 0.435 |
| Female | 310 (48) | 203 (50) | 62 (45) | 49 (45) | |
| Age, years | |||||
| Median (range) | 65 (33–92) | 64 (37–88) | 67 (33–82) | 0.134 | |
| Karnofsky Performance | |||||
| Score | |||||
| <70 | 37 (6) | 21 (5) | 7 (5) | 9 (8) | 0.049 |
| 70 | 98 (15) | 53 (13) | 25 (18) | 22 (20) | |
| 80 | 332 (52) | 228 (56) | 60 (43) | 46 (43) | |
| ≥90 | 174 (27) | 103 (26) | 45 (32) | 28 (26) | |
| Unknown | 5 (1) | 0 (0) | 2 (2) | 3 (3) | |
| Smoking Status | |||||
| Current | 168 (26) | 107 (26) | 44 (32) | 19 (18) | 0.123 |
| Former | 426 (66) | 267 (66) | 86 (62) | 77 (71) | |
| Nonsmoker | 52 (8) | 31 (8) | 9 (6) | 12 (11) | |
| Clinical Disease Stage (AJCC 6th Edn) | |||||
| IA | 40 (6) | 34 (8) | 3 (2) | 3 (3) | <0.001 |
| IB | 56 (9) | 37 (9) | 7 (5) | 12 (11) | |
| IIA | 7 (1) | 6 (1) | 2 (1) | 0 (0) | |
| IIB | 39 (6) | 20 (5) | 6 (4) | 13 (12) | |
| IIIA | 207 (32) | 137 (34) | 46 (33) | 27 (25) | |
| IIIB | 231 (36) | 146 (36) | 57 (41) | 30 (28) | |
| IV | 42 (6) | 25 (6) | 13 (9) | 4 (4) | |
| Recurrent/post-op | 10 (2) | 0 (0) | 4 (3) | 6 (6) | |
| Unknown | 14 (2) | 0 (0) | 1 (1) | 13 (12) | |
| Tumor Histology | |||||
| Adenocarcinoma | 233 (36) | 140 (35) | 52 (37) | 42 (39) | 0.003 |
| SCC | 217 (34) | 125 (30) | 46 (33) | 49 (45) | |
| NSCLC, NOS | 196 (30) | 140 (35) | 41 (30) | 17 (16) | |
| Induction Therapy* | |||||
| No | 369 (57) | 247 (61) | 78 (56) | 80 (74) | 0.012 |
| Yes | 277 (43) | 158 (39) | 61 (44) | 28 (26) | |
| Concurrent Therapy* | |||||
| No | 190 (29) | 138 (34) | 31 (22) | 38 (35) | 0.026 |
| Yes | 456 (71) | 267 (66) | 108 (78) | 70 (65) | |
| Radiation Dose | |||||
| Median (range) | 63 Gy (50.4–84) | 63 Gy (50–74.25) | 74 Gy(RBE) (50–87.5) | <0.001 | |
Abbreviations: 3D-CRT, 3-dimensional conformal radiation therapy; IMRT, intensity-modulated radiation therapy; PBT, proton beam therapy AJCC, American Joint Committee on Cancer; SCLC, small cell lung cancer; NSCLC NOS, non-small cell lung cancer not otherwise specified
*
These descriptors concern chemotherapy only. The number of patients receiving protective agents (e.g. celecoxib, amifostine) was: 3D-CRT, n=35, IMRT=11, PBT=1.